NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. More Details
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has NeoGenomics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: NEO's weekly volatility (6%) has been stable over the past year.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: NEO exceeded the US Life Sciences industry which returned 51.2% over the past year.
Return vs Market: NEO exceeded the US Market which returned 23.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is NeoGenomics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?
1 month ago | Simply Wall StThe NeoGenomics (NASDAQ:NEO) Share Price Is Up 473% And Shareholders Are Delighted
2 months ago | Simply Wall StNeoGenomics, Inc. Just Recorded A 54% EPS Beat: Here's What Analysts Are Forecasting Next
Is NeoGenomics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NEO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NEO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NEO is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: NEO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NEO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NEO is overvalued based on its PB Ratio (9.3x) compared to the US Life Sciences industry average (8.7x).
How is NeoGenomics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: NEO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NEO's is expected to become profitable in the next 3 years.
Revenue vs Market: NEO's revenue (12.1% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: NEO's revenue (12.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NEO's Return on Equity is forecast to be low in 3 years time (5.4%).
How has NeoGenomics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEO is currently unprofitable.
Growing Profit Margin: NEO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NEO is unprofitable, but has reduced losses over the past 5 years at a rate of 37.3% per year.
Accelerating Growth: Unable to compare NEO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (30.4%).
Return on Equity
High ROE: NEO has a negative Return on Equity (-0.74%), as it is currently unprofitable.
How is NeoGenomics's financial position?
Financial Position Analysis
Short Term Liabilities: NEO's short term assets ($422.4M) exceed its short term liabilities ($64.6M).
Long Term Liabilities: NEO's short term assets ($422.4M) exceed its long term liabilities ($228.5M).
Debt to Equity History and Analysis
Debt Level: NEO's debt to equity ratio (25.7%) is considered satisfactory.
Reducing Debt: NEO's debt to equity ratio has increased from 2% to 25.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if NEO has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NEO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is NeoGenomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug VanOort (65 yo)
Mr. Douglas M. VanOort, also known as Doug, has been the Chairman and Chief Executive Officer of NeoGenomics Inc. since October 28, 2009. Mr. VanOort has been the Executive Chairman and Chief Executive Off...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD3.65M) is below average for companies of similar size in the US market ($USD6.22M).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
|Chairman & CEO||11.25yrs||US$3.65m||2.11% |
|Chief Financial Officer||0.92yr||US$524.84k||0.0069% |
|President of Pharma Services Division||no data||US$1.11m||0.34% |
|President of Clinical Services Division||4.83yrs||US$1.28m||0.13% |
|Chief Medical Officer||1.17yrs||US$1.18m||0.087% |
|Manager of Investor Relations and Strategy & Corporate Development||no data||no data||no data|
|General Counsel & Corporate Secretary||2yrs||no data||0.049% |
|Chief Compliance Officer||2.67yrs||no data||no data|
|Chief Strategy & Corporate Development Officer||0.92yr||no data||no data|
|Chief Marketing Officer||0.58yr||no data||no data|
|Chief Culture Officer||4.33yrs||no data||0.022% |
|President of Informatics Division||0.42yr||US$820.15k||0.010% |
Experienced Management: NEO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|Chairman & CEO||11.25yrs||US$3.65m||2.11% |
|Independent Director||10.25yrs||US$167.55k||0.027% |
|Independent Director||0.50yr||no data||0.0015% |
|Independent Director||9.92yrs||US$182.56k||0.058% |
|Independent Director||6.25yrs||US$181.76k||0.040% |
|Lead Independent Director||0.50yr||US$183.63k||0.038% |
|Independent Director||3.5yrs||US$161.87k||0.0053% |
|Independent Director||5.58yrs||US$191.56k||0.077% |
|Independent Director||0.67yr||no data||0.0023% |
Experienced Board: NEO's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NEO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.8%.
NeoGenomics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NeoGenomics, Inc.
- Ticker: NEO
- Exchange: NasdaqCM
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$6.484b
- Shares outstanding: 115.72m
- Website: https://www.neogenomics.com
Number of Employees
- NeoGenomics, Inc.
- 12701 Commonwealth Drive
- Suite 9
- Fort Myers
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NEO||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Nov 2001|
|NG9||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2001|
|NEO *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Nov 2001|
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Ph...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/23 23:52|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.